Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
36 hedge funds and large institutions have $9.18M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 5 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
11% less call options, than puts
Call options by funds: $76K | Put options by funds: $85K
30% less capital invested
Capital invested by funds: $13.1M → $9.18M (-$3.93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$260K |
| 2 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$98.4K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$61.8K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$63K |
| 2 |
Bank of New York Mellon
New York
|
-$48K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
-$46K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$31.5K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$26.5K |
FRTX Hedge Fund Activity: Q3 2016 in Review
36 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2016, worth a combined $9.18M — down 30% from $13.1M a quarter earlier.
Fund positioning in FRTX was balanced in Q3 2016: 5 funds opened new positions, 5 closed out, 13 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $260K. The largest seller was Citadel Advisors, exiting entirely with an estimated $63K sold.
- 36 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $9.18M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2016, down 30% quarter-over-quarter.
- 5 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2016 and 5 closed out, a net change of 0 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2016 was Renaissance Technologies, an estimated $260K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2016 was Citadel Advisors, an estimated $63K sold.
Based on aggregated 13F filings for Q3 2016.